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original work is propObjective: HIV-1 frequently adapts in response to immune pressure from cytotoxic T-
lymphocytes (CTL). Many HIV-2 infected individuals have robust capsid-specific CTL
responses associated with viral control. Despite this CTL pressure, adaptive changes in
this key immunogenic HIV-2 protein have not previously been described. We sought to
compare selective pressure on HIV-1 and HIV-2 capsids and identify HLA-associated
viral polymorphisms in HIV-2.
Design andmethods: Bioinformatic algorithms to identify sites underpositiveandnegative
selective pressure and a statistical model of evolution to identifyHLA-associated polymor-
phisms inHIV-2was applied to sequences fromacommunity cohort inGuinea-Bissau. IFN-
g ELISpots were used to compare T-cell responses to wild-type and variant epitopes.
Results: We identified greater purifying selection and less sites under positive selective
pressure in HIV-2 compared with HIV-1. Five HIV-2 codons with HLA-associated
polymorphisms were detected all within or around known or predicted CTL epitopes.
One site was within theHLA-B58 SuperType (ST)-restricted epitope (TSTVEEQIQW), the
HIV-2 equivalent of the HIV-1 TW10 epitope. In contrast to HIV-1, where a T!N
mutation at position 3 is associatedwith resulting loss ofCTL control, an E!Dmutation at
position5wasobserved inHIV-2.RobustCTL responses to thevariantHIV-2epitopewere
seen, suggesting that HIV-2 adaptation may be at the level of T-cell receptor recognition.
Conclusion: Greater constraints on evolution may exist in HIV-2, resulting in more
purifying selection and different immune adaptation pathways in HIV-1 and HIV-2
capsids. This may allow CTL responses to persist in HIV-2.
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are thought to play an important role in HIV-1 control
[1–4]. A hallmark of HIV-1 evolution, however, is the
rapid appearance of mutations within CTL epitopes,
leading to loss of CTL recognition and immune control
[5]. HIV-2 differs from HIV-1 in that a substantial
proportion of infected people maintain undetectable
plasma viral loads for decades with no signs of
immunodeficiency. Many others have viral loads 30-fold
lower than HIV-1 at equivalent disease stages [6–9]. We
have previously demonstrated a strong correlation
between the presence of high frequency HIV-2 Gag-
specific CTLs and viral control [10–12]. As HIV-2 is able
to generate resistance mutations akin to HIV-1 under
antiretroviral pressure [13], HIV-2 should also have the
capacity to adapt to immune responses similar to HIV-1.
Establishing similarities anddifferences betweenHIV-1and
HIV-2 immune evasion strategies has the potential to
enhance our understanding of HIV pathogenesis. HIV-1
p24 andHIV-2 p26 represent the twomajor CTL-targeted
proteins in these viruses. Here, we provide the first
comparison of selective pressure in HIV-1 p24 and HIV-2
p26 capsid sequences froma community cohort inGuinea-
Bissau, along withHLA-associated viral polymorphisms in
HIV-2,whichmayrepresentCTL-drivenadaptivechanges.Methods
Study participants
Antiretroviral therapy (ART)-naı¨ve HIV-1 and HIV-2
mono-infected individuals from Caio, Guinea-Bissau were
recruited following written informed consent during
serosurveys and case–control studies conducted in this rural
community cohort over almost three decades [14].CD4 and
HIV-2 plasma viral load quantification [using an in-house
reverse transcriptase (RT)-PCR assay] were performed as
previously described [7,12]. Viral loadswere available in 75/
86andCD4þcounts in72/86ofHIV-2-infectedindividuals.
Median (range) viral load was 275 (<100–283542) and
CD4þ T-cell count 547.5/mm3 (100–1705). Thirty of
seventy-five (40%)hadaviral loadof less than100 copies/ml,
whichisbroadlyreflectiveofthewidercohort[15].HLAclass
I genotyping on HIV-2-infected patients was performed
during a previous study using sequencing [16,17]. Ethical
approval was provided by the jointMRC/Gambia Govern-
ment Ethics Committee, Guinea-Bissau Ministry of Health
and the Oxford Tropical Research Ethics Committee
(OXTREC), United Kingdom.
Amplification and sequencing of HIV-1 and HIV-
2 capsids
Plasma samples from 55 CRF02_AG HIV-1-infected
individuals were used to generate p24 capsid sequencesmethods, http://links.lww.com/QAD/B217). Eighty-
six HIV-2 p26 capsid sequences were used in this study:
85 previously generated sequences (GenBank accession
numbers GQ48544–GQ485550 and JX570541–
JX570562) and 1 new sequence were generated using
the same methodology [19].
Sequence analysis and tests for codon selection
Sites under positive and negative selection in HIV-1 (231
codons) and HIV-2 (230 codons) were identified by
comparison of synonymous (dS, no amino acid change)
and nonsynonymous (dN, amino acid change) substitu-
tion rates using three different methods in the
Datamonkey web-server [20]: single-likelihood ancestor
counting (SLAC), fixed-effects likelihood (FEL) and fast
unbiased Bayesian approximation (FUBAR) [21,22]
(Supplementary methods, http://links.lww.com/QAD/
B217). A P-value cut-off of 0.05 (SLAC and FEL) and
posterior probability of 0.95 (FUBAR) was used to define
significant positive or negative selection at a codon.
Identification of HLA-associated HIV-2 viral
polymorphisms
HLA-associated HIV-2 viral polymorphisms were identi-
fied using a phylogenetically corrected logistic regression,
used extensively for identifying HLA-associated HIV-1
viral polymorphisms [23]. This method corrects for
phylogenic relatedness, HLA-linkage disequilibrium and
codon covariation. Class I HLA types from 73 HIV-2-
infected adults were available for this analysis. Separate
statistical tests were constructed for eachHLA-amino acid
pair, limited to HLA alleles and amino acids that were
observed in at least 5 and at most 68 individuals. To correct
for multiple comparisons, we used a 20% false discovery
rate (threshold P< 0.0008). Epitope predictions were
made by scanning the candidate sequence for peptides of
8–11 amino acids, with each prediction made using the
supplied HLA (2% prior probability distribution).
IFN-g enzyme-linked immunosorbent spot
Cryopreserved peripheral blood mononuclear cells
(PBMCs) from HIV-2-infected patients were used in
ex-vivo IFN-g enzyme-linked immunosorbent spot
(ELISpot) assays as previously described [12], to quantify
responses to wild type and variant epitopes (Supplemen-
tary methods, http://links.lww.com/QAD/B217).Results
Fewer adaptive changes are present in HIV-2 p26
compared with HIV-1 p24
Using three different algorithms [21,22], we evaluated
selective pressure evident across the HIV-1 p24 and HIV-
2 p26 capsids. In all analyses, there were more sites under
positive selective pressure in HIV-1 p24 (6 vs. 2 in SLAC,
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sites under negative selective pressure in HIV-2 p26 (139
vs. 61 in SLAC, 157 vs. 82 in FEL and 151 vs. 131 in
FUBAR analysis); Chi-squared P< 0.0001, P <0.0001
and P¼ 0.0096, respectively, for the three algorithms. A
significantly higher mean dN/dS ratio (95% confidence
interval) of 0.249 (0.223–0.277) in HIV-1 compared
with 0.099 (0.099–0.110) in HIV-2 (P< 0.0001)
confirmed the greater purifying selection seen in HIV-
2 (i.e. selective purging of deleterious alleles).
We further characterized the sites under positive selective
pressure in HIV-1 p24 and HIV-2 p26 (Fig. 1,
Supplementary Tables 1 and 2, http://links.lww.com/
QAD/B217). The two sites under positive selection in
HIV-2 (identified by all three algorithms) are not within
any known HIV-2 CTL epitope regions, although are in
regions flanking B35 and B14-restricted epitopes,
respectively (Fig. 1). Changes in flanking residues can
affect epitope processing and presentation, therefore,
influencing CTL response [24].
Three of the four currently known HIV-2 CTL epitopes
(restricted by HLA-B14, B3501, B5301 [12]) were
conserved in 96.4, 82.6 and 97.7% of HIV-2 sequences,
respectively, despite robust ELISpot responses against
these epitopes in HLA-B14, B3501 and B5301-
positive individuals (Supplementary Table 3, http://
links.lww.com/QAD/B217). This may indicate con-
straints against evolution within these epitopes, therebyPosition     140                 160         
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contrast, all six HIV-1 p24 sites under positive selective
pressure (identified by all three algorithms) lie within
putative CTL epitopes restricted byHLA alleles common
in Caio (Supplementary Table 3, http://links.lww.com/
QAD/B217), including the well described T242N
mutation in the HLA-B57/B5801-restricted TW10
epitope (TSTLQEQIGW) [25,26].
Identification of a potential HLA-associated HIV-
2 p26 polymorphism within a known HLA-
BM5801-restricted cytotoxic T-lymphocyte
epitope
We then identified five associations between HLA alleles
and polymorphisms in HIV-2 p26 using a previously
described statistical model [23] (Table 1). Position 254
(associated with HLA-B35) is immediately upstream of
the HLA-B3501-restricted epitope NPVPVGNIY and
position 245 (associated with HLA-B58 ST) lies within
the known B57/B5801-restricted TW10-like HIV-2
epitope TSTVEEQIQW (Fig. 1). Positions 256, 294 and
313 were all within or in regions flanking predicted
epitopes restricted by the identified HLA types (Table 1).
The glutamic acid (E) to aspartic acid (D) change at
position 245 was observed in 65% of HLA-B58 ST-
positive compared with 32% of HLA-B58 ST-negative
individuals. No HIV-2 sequences had evidence of the
HIV-1 equivalent T!N mutation at position 3 (i.e.
T242N).        180                 200 
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Table 1. Potential sites of HLA-mediated selection pressure and codon evolution in HIV-2 p26 as predicted by a phylogenetic dependency
network analysis.
HIV-2 Gag
codon
Amino
acid
HLA
association Directionb P value q valuec
Predicted epitope around codon
associated with relevant HLA typed
Prediction
probability (%)
245 D B58_STa Adapted 0.0002 0.0684 STVDEQIQWe 94
245 E B58_ST Nonadapted 6.73E-05 0.0309 STVEEQIQWe 92
254 A B35 Nonadapted 0.0002 0.1030 FRAQNPVPVGNIYRRWf 71
254 P B35 Adapted 0.0001 0.0336 FRPQNPVPVGNIYRRWf 71
254 P C08 Adapted 8.89E-05 0.0336 WMFRPQNPVPV 53
256 V A03_STa Adapted 0.000749 0.1721 NPVPVGNIYRR 51
256 I A03_ST Nonadapted 0.000749 0.1721 NPIPVGNIYRR 57
294 S C0401 Nonadapted 2.79E-07 0.0002 ESFQSYVDRFYKSLRA 60
294 P C0401 Adapted 1.10E-07 8.32E-05 EPFQSYVDRFYKSLRA 60
313 A B5801 Adapted 4.93E-08 5.66E-05 QTDAAVKNW 66
313 P B5801 Nonadapted 1.79E-10 4.11E-07 QTDPAVKNW 65
aST, SuperType (15).
bAdapted indicates that reported amino acid is the putative adaption at that site (i.e. ‘escaped’ variant). Nonadapted indicates that reported amino
acid is putatively susceptible to escape (i.e. ‘reversion’).
cEstimation of false-discovery rate for each association, that is, q value of 0.05¼5% false discovery rate.
dWherever codon is in flanking region, epitope is underlined. Codon is shown in bold. Epitope predictions are made by scanning the candidate
sequence for peptide lengths of 8–11 amino acids. Only peptides within three amino acids of the associated codon are considered.
eThe 10-mer TSTVEEQIQW has been previously identified as a B58_ST-restricted epitope via functional assays. The prediction algorithm used
identifies the 9-mer STVDEQIQW as an optimal B58_ST-restricted epitope.
fNPVPVGNIY is a known BM35-restricted epitope.Robust T-cell responses to the HIV-2 TW10-like
wildtype and mutant epitopes despite the
presence of the E245D polymorphism in HLA
BM5801-positive individuals
T242N escape within the HIV-1 TW10 epitope occurs
early after infection, impactsHLA binding, leading to loss
of CTL recognition and carries a fitness cost overcome by
compensatory mutations [25,26]. As robust CTL
responses are found in HIV-2-infected individuals
decades after infection [10,12], we examined IFN-g
ELISpot responses to both wildtype HIV-2 (TSTVEE-
QIQW) and E245D variant (TSTVDEQIQW) peptides.
ELISpot responses to both peptide variants were observed
in almost all individuals (Supplementary Table 4, http://
links.lww.com/QAD/B217), including robust responses
to the E245D mutant peptide. In all but one individual,
the response was stronger against the peptide that
matched the individual’s autologous virus sequence,
suggesting that the T-cell response in these individuals
could adapt to overcome this particular CTL epitope
polymorphism in HIV-2. In three donors where
sufficient PBMCs were available to test, none had
cross-reactive responses to HIV-1 TW10 (Supplementary
Table 4, http://links.lww.com/QAD/B217).Discussion
We report the first analysis of HLA-associated viral
polymorphisms in HIV-2 p26, including a codon
substitution within a known immunodominant HLA-
B5801-restricted epitope. This may represent CTL-
driven adaptation by HIV-2 and allows direct comparison
with what is known about the equivalent HLA-B57/
B5801-restricted epitope inHIV-1. In contrast toHIV-1,wherever a mutation at position 3 of the epitope (T242N)
occurs in 63–93% of HLA-B5801-positive individuals
[25], a mutation at position 5 (E245D) is found in 65% of
HLA-B58 ST-positive patients. TheHIV-1TW10 epitope
lies within a region essential for capsid formation [27] and
residue 242 is thought to be critical to stabilizing the
electrostatic charge along helix 6 [26]. AT242Nmutation
reduces this stabilizing effect [26], consistent with viable
viruswith significantly reduced fitness. It is possible that for
HIV-2, with much lower in-vivo viral titres than HIV-1,
the fitness costs of such amutation are too severe, leading to
an alternative pathway of immune adaptation. Further
functional studies are required to explore this hypothesis.
The E!D mutation found in HIV-2 replaces one
hydrophilic, negatively charged, amino acid with another.
In contrast to HIV-1 where T242N escape usually results
in loss of immune control, robust CTL responses are
generated against this HIV-2 mutant. The absence of
E245D mutant responses in one participant (B58_8,
Supplementary Table 4, http://links.lww.com/QAD/
B217) suggests that these E245D variant responses do not
simply represent cross-reactive CTLs. The presence of
CTLs specific to both variants in most individuals may
reflect low-level persistence of epitope variants in the viral
population not detected by bulk PCR sequencing used in
this study. These data also imply that this potential HIV-2
immune adaptation is at the level of T-cell receptor
recognition of the peptide–MHC complex, as peptide
processing and MHC-epitope binding of E245D variants
are presumably still maintained.
We also describe the first comparison of selective pressure
on HIV-1 and HIV-2 capsids, finding greater purifying
selective pressure in HIV-2. We reported similar findings
in HIV-2 env, where relative conservation of this highly
HLA-associated polymorphisms in the HIV-2 capsid de Silva et al. 713variable gene is seen despite high magnitude autologous
neutralizing antibody titres [28]. Although one explana-
tion for the lower adaptive changes in HIV-2 is lower viral
replication compared with HIV-1, previous studies have
demonstrated that evolutionary rates are equivalent if not
faster in advanced HIV-2 than in HIV-1 infection [29].
Furthermore, the emergence of ART-driven resistance
mutations in HIV-2 shows that at least in the reverse
transcriptase and protease genes, viral escape can readily
occur [13].
A key limitation of our study is the lack of longitudinal
data following individual patients from acute HIV-2
infection to demonstrate CTL-driven escape, shown
extensively in HIV-1 [1–5]. Although such a study would
add considerable insight, the reducing incidence of HIV-
2 infection in West Africa, on a background of vastly
lower transmission rates than HIV-1, makes this
challenging [14,30]. Acute HIV-2 infection is difficult
to identify, and therefore, rarely described. As an indirect
way of investigating the issue of HIV-2 immune
adaptation, we have, therefore, utilized a statistical model
of evolution, well validated in HIV-1 cohorts [23,31].
The significant proportion of HIV-2-infected individuals
with low viral loads make generating sequence data
challenging (approximately 50% success if viral load
<100 copies/ml [19]) and could lead to a biased dataset
whenever compared with HIV-1. Nevertheless, our
dataset represents the largest collection of sequence data
generated from HIV-2-infected individuals with viral
load less than 100 copies/ml to date [19].
In conclusion, we provide the first evidence of adaptive
changes in the HIV-2 capsid. Our data highlight
fundamental differences in immune adaptation between
HIV-1 and HIV-2, suggesting that HIV-2 evolution may
be limited in this region. Further functional studies are
required to characterize the polymorphisms identified in
HIV-2, validate our findings and explore whether this
characteristic explains why robust immune responses can
persist in HIV-2-infected individuals for many years. This
in turn may underpin the diverse outcomes seen in HIV-1
and HIV-2 infections, providing a crucial clue to the yet
unsolved conundrum of the relatively attenuated nature
of most HIV-2 infections.Acknowledgements
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